Sequence-specific in vivo cell targeting
AssigneesGflas Life Sciences, Inc., Seoul National University R&Db Foundation
InventorsSungyong In, Sunghwa Choe, Mi Jin Park, Aiden Y. Park, Jung Hak Lim, Dong Wook Kim, Youngdong Yoo, Jongjin Park
Life of this patent
Estimating the term…
Abstract
Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
Claims10
A method of inducing cell death of a cancer cell in a tissue of a subject in need thereof, the method comprising:
- a) administering to the subject a chimeric polypeptide comprising a first domain comprising a Cas9 domain with endonuclease activity and a second domain comprising RecJ domain with exonuclease activity, and a guide nucleic acid comprising a sequence complementary to a target nucleic acid in the cancer cell, wherein the target nucleic acid is an oncogene;
- and
- b) cleaving the target nucleic acid, thereby inducing cell death of the cancer cell.
Dependencies are inferred from the claim text.